Get notified of page updates

Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

Clinicaltrials.gov identifier:
NCT04673448
PRINTER FRIENDLY PAGE

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

Clinicaltrials.gov identifier:
NCT04673448
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

About the Study

NOTE: This study is no longer recruiting people. 

 

This study is looking at the effectiveness of combining a called and an called dostarlimab for treating people with an inherited mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, or primary peritoneal cancer that is or advanced and cannot be removed by surgery (unresectable).

 

This Study is Open To:

NOTE: This study is no longer recruiting people. 

This Study is NOT Open To:

NOTE: This study is no longer recruiting people.